Literature DB >> 25339437

Improvement of gagCEST imaging in the human lumbar intervertebral disc by motion correction.

Anja Müller-Lutz1, Christoph Schleich, Benjamin Schmitt, Melike Topgöz, Gael Pentang, Gerald Antoch, Hans-Jörg Wittsack, Falk Miese.   

Abstract

OBJECTIVE: To investigate whether motion correction improves glycosaminoglycan chemical exchange saturation transfer imaging (gagCEST imaging) of intervertebral discs (IVDs).
MATERIALS AND METHODS: Magnetic resonance gagCEST imaging of 12 volunteers was obtained in lumbar IVDs at 3 T using a prototype pulse sequence. The data were motion-corrected using a prototype diffeomorphism-based motion compensation technique. For both the data with and that without motion correction (datac, datauc), CEST evaluation was performed using the magnetisation transfer ratio asymmetry (MTRasym) as a means of quantifying CEST effects. MTRasym and the signal-to-noise ratio (SNR) of the MTRasym map in the nucleus pulposus (NP) were compared for datac and datauc. A visual grading analysis was performed by a radiologist in order to subjectively quantify the quality of the MTRasym analysis (score 1: best quality, score 5: worst quality). Furthermore, a landmark analysis was performed in order to objectively quantify the motion between CEST images using the mean landmark distance dmean.
RESULTS: MTRasym and SNR were significantly higher for the motion-corrected data than for the uncorrected CEST data (MTRasym(datac) = 3.77 % ± 0.95 %, MTRasym(datauc) = 3.41 % ± 1.54 %, p value = 0.001; SNR(datac) = 3.88 ± 2.04, SNR(datauc) = 2.77 ± 1.55, p value < 0.001, number of IVDs = 48). The visual grading analysis revealed a higher reliability for datac (maximum score = 2) compared with datauc (maximum score = 5). The landmark analysis demonstrated the superiority of the motion-corrected data (dmean(datac) = 0.08 mm ± 0.09 mm, dmean(datauc) = 0.36 mm ± 0.09 mm, p value = 0.001).
CONCLUSION: Our study showed significant improvements in the ability to quantify CEST imaging in IVDs after the application of motion correction compared with uncorrected datasets.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339437     DOI: 10.1007/s00256-014-2034-z

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  27 in total

1.  In vivo sodium MR imaging of the intervertebral disk at 4 T.

Authors:  Erik K Insko; David B Clayton; Mark A Elliott
Journal:  Acad Radiol       Date:  2002-07       Impact factor: 3.173

2.  Molecular imaging of cartilage damage of finger joints in early rheumatoid arthritis with delayed gadolinium-enhanced magnetic resonance imaging.

Authors:  Falk Miese; Christian Buchbender; Axel Scherer; Hans-Jörg Wittsack; Christof Specker; Matthias Schneider; Gerald Antoch; Benedikt Ostendorf
Journal:  Arthritis Rheum       Date:  2012-02

3.  Low back pain in relation to lumbar disc degeneration.

Authors:  K Luoma; H Riihimäki; R Luukkonen; R Raininko; E Viikari-Juntura; A Lamminen
Journal:  Spine (Phila Pa 1976)       Date:  2000-02-15       Impact factor: 3.468

4.  Correlation between T2 relaxation time and intervertebral disk degeneration.

Authors:  Hiroyuki Takashima; Tsuneo Takebayashi; Mitsunori Yoshimoto; Yoshinori Terashima; Hajime Tsuda; Kazunori Ida; Toshihiko Yamashita
Journal:  Skeletal Radiol       Date:  2011-03-23       Impact factor: 2.199

5.  Imaging the pH evolution of an acute kidney injury model by means of iopamidol, a MRI-CEST pH-responsive contrast agent.

Authors:  Dario Livio Longo; Alice Busato; Stefania Lanzardo; Federica Antico; Silvio Aime
Journal:  Magn Reson Med       Date:  2012-10-11       Impact factor: 4.668

6.  Quantitative T2 evaluation at 3.0T compared to morphological grading of the lumbar intervertebral disc: a standardized evaluation approach in patients with low back pain.

Authors:  David Stelzeneder; Goetz Hannes Welsch; Balázs Krisztián Kovács; Sabine Goed; Tatjana Paternostro-Sluga; Marianna Vlychou; Klaus Friedrich; Tallal Charles Mamisch; Siegfried Trattnig
Journal:  Eur J Radiol       Date:  2011-02-18       Impact factor: 3.528

7.  Assessment of glycosaminoglycan distribution in human lumbar intervertebral discs using chemical exchange saturation transfer at 3 T: feasibility and initial experience.

Authors:  Mina Kim; Queenie Chan; Marina-Portia Anthony; Kenneth M C Cheung; Dino Samartzis; Pek-Lan Khong
Journal:  NMR Biomed       Date:  2011-03-08       Impact factor: 4.044

8.  Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002.

Authors:  Richard A Deyo; Sohail K Mirza; Brook I Martin
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-01       Impact factor: 3.468

9.  Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments.

Authors:  Mina Kim; Joseph Gillen; Bennett A Landman; Jinyuan Zhou; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2009-06       Impact factor: 4.668

10.  Ex vivo porcine model to measure pH dependence of chemical exchange saturation transfer effect of glycosaminoglycan in the intervertebral disc.

Authors:  Gerd Melkus; Michelle Grabau; Dimitrios C Karampinos; Sharmila Majumdar
Journal:  Magn Reson Med       Date:  2013-07-01       Impact factor: 4.668

View more
  7 in total

1.  Real-time simultaneous shim and motion measurement and correction in glycoCEST MRI using double volumetric navigators (DvNavs).

Authors:  Gizeaddis L Simegn; Andre J W Van der Kouwe; Frances C Robertson; Ernesta M Meintjes; Ali Alhamud
Journal:  Magn Reson Med       Date:  2018-12-02       Impact factor: 4.668

2.  Comparison of B0 versus B0 and B1 field inhomogeneity correction for glycosaminoglycan chemical exchange saturation transfer imaging.

Authors:  Anja Müller-Lutz; Alexandra Ljimani; Julia Stabinska; Moritz Zaiss; Johannes Boos; Hans-Jörg Wittsack; Christoph Schleich
Journal:  MAGMA       Date:  2018-05-14       Impact factor: 2.310

3.  Biochemical imaging of cervical intervertebral discs with glycosaminoglycan chemical exchange saturation transfer magnetic resonance imaging: feasibility and initial results.

Authors:  Christoph Schleich; Anja Müller-Lutz; Lisa Zimmermann; Johannes Boos; Benjamin Schmitt; Hans-Jörg Wittsack; Gerald Antoch; Falk Miese
Journal:  Skeletal Radiol       Date:  2015-09-16       Impact factor: 2.199

4.  Functional MR imaging beyond structure and inflammation-radiographic axial spondyloarthritis is associated with proteoglycan depletion of the lumbar spine.

Authors:  Daniel B Abrar; Christoph Schleich; Styliani Tsiami; Anja Müller-Lutz; Karl Ludger Radke; Neela Holthausen; Miriam Frenken; Matthias Boschheidgen; Gerald Antoch; Johanna Mucke; Philipp Sewerin; Juergen Braun; Sven Nebelung; Xenofon Baraliakos
Journal:  Arthritis Res Ther       Date:  2020-09-17       Impact factor: 5.156

5.  Non-Specific Low Back Pain and Lumbar Radiculopathy: Comparison of Morphologic and Compositional MRI as Assessed by gagCEST Imaging at 3T.

Authors:  Miriam Frenken; Sven Nebelung; Christoph Schleich; Anja Müller-Lutz; Karl Ludger Radke; Benedikt Kamp; Matthias Boschheidgen; Lena Wollschläger; Bernd Bittersohl; Gerald Antoch; Markus R Konieczny; Daniel B Abrar
Journal:  Diagnostics (Basel)       Date:  2021-02-26

6.  Detection of early cartilage degeneration in the tibiotalar joint using 3 T gagCEST imaging: a feasibility study.

Authors:  Daniel B Abrar; Christoph Schleich; Sven Nebelung; Anja Müller-Lutz; Karl Ludger Radke; Miriam Frenken; Julia Stabinska; Alexandra Ljimani; Hans-Jörg Wittsack; Gerald Antoch; Bernd Bittersohl; Tobias Hesper
Journal:  MAGMA       Date:  2020-07-28       Impact factor: 2.310

7.  Evaluating Lumbar Intervertebral Disc Degeneration on a Compositional Level Using Chemical Exchange Saturation Transfer: Preliminary Results in Patients with Adolescent Idiopathic Scoliosis.

Authors:  Lena M Wollschläger; Sven Nebelung; Christoph Schleich; Anja Müller-Lutz; Karl L Radke; Miriam Frenken; Matthias Boschheidgen; Max Prost; Gerald Antoch; Markus R Konieczny; Daniel B Abrar
Journal:  Diagnostics (Basel)       Date:  2021-05-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.